Showing 31-40 of 2318 results for "".
Understanding the Cosmetic Patient
https://practicaldermatology.com/topics/practice-management/understanding-the-cosmetic-patient/18785/Laurie Hurt, Marketing Director for Cosmetic Surgery and Dermatology at CareCredit, shares insights on the research and buying habits of cosmetic surgery patients gleaned from The Path to Purchase Study.Patient Portals
https://practicaldermatology.com/topics/practice-management/patient-portals/19113/Michael J. Sacopulos, JD, Founder and President of Medical Risk Institute (www.medriskinstitute.com), addresses the role, benefits, and potential pitfalls of patient portals.How to Deal with Hagglers and Other Tough Patients
https://practicaldermatology.com/topics/practice-management/how-to-deal-with-hagglers-and-other-tough-patients/19211/Michael J. Sacopulos, JD offers strategies for handling difficult patients and how to negotiate with hagglers.BroadBand Light BBL - Patient Testimonials
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/broadband-light-bbl-patient-testimonials/19466/Patients describe their experience with sciton BroadBand Light (BBL).Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toPart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Part 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.Taking a More Holistic View of the Pathogenesis of Acne
https://practicaldermatology.com/topics/acne-rosacea/taking-more-holistic-view-pathogenesis-acne/26539/Taking a More Holistic View of the Pathogenesis of AcneThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeHidradenitis Suppurativa: A Patient’s Perspective
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-a-patients-perspective/27171/Adam Friedman, MD, FAAD, presents a first-hand account of a patient living with hidradenitis suppurativa (HS).